Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections.

Cancer Lett

Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Section 111A, Denver Veterans Affairs Medical Center, 1055 Clermont St, Denver, CO 80220-3808, USA.

Published: August 2003

Murine pulmonary adenomas progress to malignancy with many similarities to human pulmonary adenocarcinoma, the most common form of lung cancer. Inbred mice vary in their susceptibility to lung tumor development, and induced genetic modifications are a powerful tool for understanding this susceptibility. Many transgenic and null mutations relevant to lung cancer pathogenesis were derived on the highly resistant C57BL/B6 (B6) background. Since the inability to reliably induce lung tumors in B6 mice limits these studies, we systematically examined several carcinogenesis protocols in B6 mice. Ten weekly ethyl carbamate (EC) doses caused a nearly 100% lung tumor incidence with a tumor multiplicity >2; multiple EC dosing is thus an alternative to the time-consuming transfer of transgenes and null mutations to susceptible backgrounds.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0304-3835(03)00309-4DOI Listing

Publication Analysis

Top Keywords

lung tumors
8
ethyl carbamate
8
lung cancer
8
lung tumor
8
null mutations
8
lung
6
induction high
4
high incidence
4
incidence lung
4
tumors c57bl/6
4

Similar Publications

Introduction: Recent advances in the treatment of -mutant non-small cell lung cancer (NSCLC) have led to the development of KRAS inhibitors, such as sotorasib and adagrasib. However, resistance and disease progression remain significant challenges. In this study, we investigated the therapeutic potential of combining trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody-drug conjugate, with sotorasib in -mutant NSCLC, while also evaluating HER2 expression in NSCLC samples.

View Article and Find Full Text PDF

The 1.7 kb DRAIC long noncoding RNA inhibits tumor growth, inhibits cancer cell invasion, migration, colony formation and interacts with IKK (IκB kinase) subunits, inhibiting the phosphorylation and degradation of the NF-κB inhibitor, IκB, to suppress the activation of NF-κB. Whether these activities are all linked is unclear.

View Article and Find Full Text PDF

Tertiary lymphoid structures (TLS) are organized immune cell aggregates that arise in chronic inflammatory conditions. In cancer, TLS are associated with better prognosis and enhanced response to immunotherapy, making these structures attractive therapeutic targets. However, the mechanisms regulating TLS formation and maintenance in cancer are incompletely understood.

View Article and Find Full Text PDF

Imaging-based spatial transcriptomics (ST) is evolving rapidly as a pivotal technology in studying the biology of tumors and their associated microenvironments. However, the strengths of the commercially available ST platforms in studying spatial biology have not been systematically evaluated using rigorously controlled experiments. In this study, we used serial 5-m sections of formalin-fixed, paraffin-embedded surgically resected lung adenocarcinoma and pleural mesothelioma tumor samples in tissue microarrays to compare the performance of the single cell ST platforms CosMx, MERFISH, and Xenium (uni/multi-modal) platforms in reference to bulk RNA sequencing, multiplex immunofluorescence, GeoMx Digital Spatial Profiler, and hematoxylin and eosin staining data for the same samples.

View Article and Find Full Text PDF

Introduction: The relationship between immune-related thyroid dysfunction (irTD) and survival rates in cancer patients remains unclear. Furthermore, the impact of variations in immunotherapy line numbers and pathological types among lung cancer patients on this relationship has not been fully elucidated. This study aims to evaluate the potential of irTD as a prognostic marker for immunotherapy in Chinese patients with lung cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!